Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 17.4%, free cash flow fell 15.5% and total debt rose 52.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three, operating cash flow growth for three.

150.62 0.24 +0.16%
Market cap
$275.3B
P/E
22.6×
Fwd P/E
20.6×
Dividend yield
3.15%
F-score
8/9
Altman Z
4.13
Beneish M
−2.49
Dividend safety
66/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

32.64% 30.84% 34.98% 30.37%
Piotroski F-Score
7 8 5 5
ROA
13.65% 13.12% 12.39% 11.27%
ROIC
16.85% 16.10% 13.97% 13.14%
Return on Tangible Assets
215.66% 100.14% 229.90% 202.88%
Average Days of Receivables
58.17 58.88 61.95 63.44
Free Cash Flow per Share
8.93 7.95 8.45 7.97
Free Cash Flow
17,207.00 15,421.00 16,128.00 15,177.00
Other line items

Show all line items

Columns are period end dates